We would like to thank the author for his interest in our report and his thoughtful and deep comments. As the author has emphasized, this is the first study showing that carvedilol, which is both ab unselective j3- and a-adrenergic antagonist, may reduce lower urinary tract symptoms (LUTS) in patients with benign prostate hyperplasia and hypertension. However, risk of heart failure limits the use of a-antagonists in patients with left ventricle dysfunction. Although urologists may still successfully use these drugs in patients with LUTS, cardiologists are reluctant to prescribe them in cardiovascular disorders and in those relevant concerns where expressed in the author's comments.
展开▼
